Neurofibromatosis Type 1

Neurofibromatosis Type 1 is the indication for 2 drugs in DrugBank. It is covered by 2 curated, structured indications.

Also known as: Neurofibromatosis 1 · NF1 · Neurofibromatosis Type I · Von Recklinghausen Disease · NF 1
Classified under: Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Eye Disease
Musculoskeletal and Connective Tissue Diseases
Neoplasms
Nervous System Diseases
Physical Examination
Signs, Symptoms, and General Pathologies
Skin and Subcutaneous Tissue Diseases
Skin and subcutaneous tissue disorders congenital NEC
Indicated drugs: Mirdametinib
Selumetinib

Resolves to

Vocabularies

MeSHM0014710ICD-10Q85.00SNOMED CT154642000MedDRA10029268UMLSC0027831

What you can answer from here — as of October 24, 2026

2Indicated drugsWith each drug's targets and mechanism

Listed above

2Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

100Clinical trialsPhase, status and sponsor resolved per trial

2Drugs reporting it as an adverse effectWith incidence where the label states it

Which approved drugs for Neurofibromatosis Type 1 share a target, and which companies have late-stage candidates against it?

Create a free account or log in to explore the full data card.